A Study to Investigate the Safety and Clinical Effect of Nexagon® to Treat Persistent Epithelial Defects
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00821561
Recruitment Status :
(Withdrawn prior to recruitment for business reasons.)
A Phase 2, Randomized, Prospective, Double-masked, Vehicle-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Nexagon® in Subjects With Persistent Corneal Epithelial Defects (PED) From Chemical Burn Injuries.
Study Start Date :
Estimated Primary Completion Date :
Estimated Study Completion Date :
Resource links provided by the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Male and female subjects aged 18 years and over.
Subjects who are able to attend all follow-up visits and who are able to comply with all study procedures.
Subjects who are willing and able to give written informed consent to take part in the study.
At the Day -7 visit subjects must have a corneal epithelial defect that has persisted for between 7 days and 14 days, which has a minimum diameter of 2 mm along the greatest axis, and which has not shown improvement despite conventional treatment such as tear supplements and bandage contact lenses.
The original defect to the cornea must have been caused by either alkaline or acidic agents.
Use of concomitant ocular medications in the screening period that are not specified in standardized PED treatment regime
Likely to require the use of concomitant ocular medications that are not specified in the standardized PED treatment regime during the study follow-up period
Decrease or increase in the PED by more than 30% during the screening period.
Have an active lid or ocular infectious process of any sort
Subjects with corneal perforation or impending corneal perforation
The circumference affected by limbal blood vessel ischemia is greater than 75% of the circumference
Subjects with severe lid abnormalities contributory to the persistence of the PED such as inability to close the lids.
Subjects with bilateral PED, if the smaller PED has a longest diameter of > 2 mm.
Female subjects who are pregnant or breastfeeding. F
Subjects who have a history of AIDS or HIV.
Subjects with any other condition which, in the Investigator's opinion, would exclude the subject from participating.
Treatment with systemic corticosteroids (equivalent to > 10 mg/day of prednisone) or immunosuppressive or chemotherapeutic agents within 7 days prior to Day 0, or likely to receive one of these therapies during study participation
Subjects who have participated in a clinical trial within 30 days prior to Day 0.
Diabetics with an HbA1c greater than 6.5%.
Diabetics who are currently prescribed more than one oral medication for their diabetes.
Subjects who have more than one distinct PED in the study eye.